62nd ASH Annual Meeting and Exposition: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Lymphoma

Oral and Poster Abstracts
Oral

Adult, ALL, AML, Biological, Follicular Lymphoma, Leukemia, survivorship, Diseases, CLL, Lymphoma (any), neurotoxicity, Non-Biological, Hodgkin Lymphoma, Combinations, Therapies, Non-Hodgkin Lymphoma, Adverse Events, checkpoint inhibitors, chemotherapy, MDS, Pediatric, B-Cell Lymphoma, Young Adult, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement

Moderators:

Pallawi Torka, MD, Roswell Park Comprehensive Cancer Center and Carrie A. Thompson, MD, Mayo Clinic

Disclosures:

No relevant conflicts of interest to declare.

9:30 AM

370

Prevalence and Predictors of Neurocognitive Impairment in Long-Term Survivors of Childhood Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study

Annalynn M Williams, PhD¹, Mengqi Xing, MR²^*, Sedigheh Mirzaei Salehabadi, PhD³^*, Yutaka Yasui, PhD⁴^*, Matt J. Ehrhardt, MD, MS¹, Rebecca M Howell, PhD⁵^*, Kevin C Oeffinger, MD⁶^*, Todd Gibson, PhD⁷^*, Eric Chow, MD⁸^*, Wendy Leisenring, ScD⁸^*, Deokumar Srivastava, PhD⁹^*, Leslie L. Robison, PhD¹^*, Gregory T Armstrong, MD¹^* and Kevin R. Krull, PhD¹^*

¹Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN
²Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
³Department of Biostatistics, St. Jude Children's Research Hospiatl, Memphis, TN
⁴Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis
⁵University of Texas MD Anderson Cancer Center, Houston, TX
⁶Duke University School of Medicine, Durham, NC
⁷St. Jude Children's Research Hospital, Memphis, TN
⁸Fred Hutchinson Cancer Research Center, Seattle, WA
⁹Department of Biostatistics, St. Jude Children's Research Hospital, memphis, TN

9:45 AM

371

Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas

Robert M. Kraft, MD¹^*, Melissa C. Larson, MS²^*, Kathleen J. Yost, PhD³^*, Thomas M. Habermann, MD⁴, Matthew J. Maurer, MS⁵, William R. Macon, MD⁶^*, Umar Farooq, MD⁷, David J. Inwards, MD⁴, Gita Thanarajasingam, MD⁴, Brian K. Link, MD⁷, James R. Cerhan, MD, PhD³ and Carrie A. Thompson, MD⁴

¹Department of Internal Medicine, Mayo Clinic, Rochester, MN
²Mayo Clinic, Rochester, MN
³Department of Health Sciences Research, Mayo Clinic, Rochester, MN
⁴Division of Hematology, Mayo Clinic, Rochester, MN
⁵Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN
⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
⁷Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

10:00 AM

372

Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study

Qing Huang, PhD¹^*, Kathleen L Deering²^*, Qing Harshaw, MD, PhD²^*, Tarun Bhagnani, MS³^* and Lori A. Leslie, MD⁴

¹Janssen Scientific Affairs, LLC, Horsham, PA
²EPI-Q Inc., Oak Brook, IL
³EPI-Q, Inc, Oak Brook, IL
⁴John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

10:15 AM

373

Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health

Dai Chihara, MD, PhD¹, Erich P. Huang, PhD²^*, Shanda R. Finnigan, MPH, RN²^*, Lisa M. Cordes, PharmD³^*, Nebojsa Skorupan, MD⁴^*, Yoko Korenaga Fukuda, MD², Larry V. Rubinstein, PhD²^* and Naoko Takebe, MD, PhD²^*

¹Medical Oncology Service, National Institute of Health, Bethesda, MD
²Division of Cancer Treatment and Diagnosis, National Institutes of Health, Bethesda
³Genitourinary Malignancies Branch, National Institutes of Health, Bethesda
⁴Medical Oncology Service, National Institutes of Health, Bethesda

10:30 AM

374

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Pier Luigi Zinzani, MD¹, Radhakrishnan Ramchandren², Armando Santoro³^*, Ewa Paszkiewicz-Kozik⁴^*, Robin Gasiorowski⁵, Nathalie A Johnson, MD, PhD⁶, José S. R. de Oliveira⁷^*, Valeria Buccheri⁸^*, Guilherme Fleury Perini⁹^*, Michael Dickinson, MBBS, FRACP, FRCPA¹⁰, Andrew McDonald¹¹^*, Muhit Ozcan, MD¹², Naohiro Sekiguchi¹³^*, Monika Raut¹⁴^*, Hilde Giezek¹⁴^*, Akash Nahar¹⁴^* and John Kuruvilla, MD¹⁵

¹Institute of Hematology “L. e A. Seràgnoli” – University of Bologna, Bologna, Italy
²University of Tennessee, Knoxville, TN
³Department of Biomedical Sciences, Humanitas Clinical and Research Center IRCCS Rozzano-Milano, Milan, Italy
⁴Maria Sklodowska-Curie National Institute of Oncology, Warsaw, Poland
⁵Concord Hospital, University of Sydney, Sydney, NSW, Australia
⁶Jewish General Hospital, Lady Davis Institute for Medical Research and Segal Cancer Centre, Montreal, QC, Canada
⁷Casa de Saúde Santa Marcelina, São Paulo, Brazil
⁸Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
⁹Hospital Israelita Albert Einstein, São Paulo, Brazil
¹⁰Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
¹¹Pretoria East Hospital, Pretoria, South Africa
¹²Ankara University School of Medicine, Ankara, Turkey
¹³National Hospital Organization Disaster Medical Center, Tokyo, Japan
¹⁴Merck & Co., Inc., Kenilworth, NJ
¹⁵The Princess Margaret Hospital, Toronto, ON, Canada

10:45 AM

375

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vit K Prochazka, MD, PhD¹^*, Štěpánka Matuštíková²^*, Tomáš Fürst, Dr.³^*, David Belada, MD, PhD⁴^*, Andrea Janíková, MD, PhD, Assoc Prof⁵^*, Kateřina Benešová, MD, PhD⁶^*, Heidi Mociková, MD⁷^*, Juraj Ďuraš, MD⁸^*, Jan Pirnos, MD⁹^*, Kateřina Kopečková, MD, PhD¹⁰^*, Vít Campr, MD, PhD¹¹^*, Jozef Michalka, MD¹²^*, Robert Pytlík, MD¹³^*, Tomáš Papajík, MD, prof¹⁴^* and Marek Trněný, MD, prof¹⁵

¹Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital In Olomouc, Olomouc, Czech Republic
²Faculty of Science, Palacký University, Olomouc, Czech Republic
³Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacký University, Olomouc, Czech Republic
⁴4th Department of Internal Medicine – Hematology, University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
⁵Department of Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic
⁶Ist Dept Medicine, 1st Fac Medicine, Charles University, General Hospital, Prague, CZE
⁷Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, AE, Czech Republic
⁸Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
⁹Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
¹⁰University Hospital Motol, Praha, Czech Republic
¹¹Department of Pathology and Molecular Medicine, University Hospital in Motol, Prague, and Second Faculty of Medicine, Prague, Czech Republic
¹²Masaryk University, Brno, Czech Republic
¹³1st Department of Medicine - Hematooncology, First Faculty of Medicine and General Teaching Hospital, Praha 2, Czech Republic
¹⁴Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
¹⁵First Dept. of Medicine- Hematology, Charles University General Hospital and First Faculty of Medicine, Praha 2, Czech Republic

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

905.O1.6 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Lymphoma